Our findings suggest KRT17+KRT5– cells represent a convergent pathogenic mechanism in lung fibrosis, making them attractive therapeutic targets for CLAD, where treatment options remain severely limited. This evidence concerns the gene KRT5 and pulmonary fibrosis.